BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30772267)

  • 1. Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak.Bcl-xl complex.
    Zhang G; Ma F; Li L; Li J; Li P; Zeng S; Sun H; Li E
    Biochem Pharmacol; 2019 May; 163():133-141. PubMed ID: 30772267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor potential of 15,16-dihydrotanshinone I against breast adenocarcinoma through inducing G1 arrest and apoptosis.
    Tsai SL; Suk FM; Wang CI; Liu DZ; Hou WC; Lin PJ; Hung LF; Liang YC
    Biochem Pharmacol; 2007 Dec; 74(11):1575-86. PubMed ID: 17869226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bufalin induces G0/G1 phase arrest through inhibiting the levels of cyclin D, cyclin E, CDK2 and CDK4, and triggers apoptosis via mitochondrial signaling pathway in T24 human bladder cancer cells.
    Huang WW; Yang JS; Pai SJ; Wu PP; Chang SJ; Chueh FS; Fan MJ; Chiou SM; Kuo HM; Yeh CC; Chen PY; Tsuzuki M; Chung JG
    Mutat Res; 2012 Apr; 732(1-2):26-33. PubMed ID: 22285700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
    Jin X; Ge LP; Li DQ; Shao ZM; Di GH; Xu XE; Jiang YZ
    Mol Cancer; 2020 May; 19(1):87. PubMed ID: 32393270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylation of Rad9 at serine 328 by cyclin A-Cdk2 triggers apoptosis via interfering Bcl-xL.
    Zhan Z; He K; Zhu D; Jiang D; Huang YH; Li Y; Sun C; Jin YH
    PLoS One; 2012; 7(9):e44923. PubMed ID: 23028682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
    Long Q; Ma AH; Zhang H; Cao Z; Xia R; Lin TY; Sonpavde GP; de Vere White R; Guo J; Pan CX
    Cancer Immunol Immunother; 2020 Nov; 69(11):2305-2317. PubMed ID: 32506263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma.
    Chen T; Liu L; Zou Y; Hu X; Zhang W; Zhou T; Luo X; Fu W; Xu J
    Cancer Biol Med; 2021 Feb; 18(1):227-244. PubMed ID: 33628597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
    AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
    Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma.
    Ho IL; Kuo KL; Liu SH; Chang HC; Hsieh JT; Wu JT; Chiang CK; Lin WC; Tsai YC; Chou CT; Hsu CH; Pu YS; Shi CS; Huang KH
    Sci Rep; 2015 Nov; 5():16948. PubMed ID: 26592553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phthalazino[1,2-b]quinazolinones as p53 Activators: Cell Cycle Arrest, Apoptotic Response and Bak-Bcl-xl Complex Reorganization in Bladder Cancer Cells.
    Zhang GH; Yuan JM; Qian G; Gu CX; Wei K; Mo DL; Qin JK; Peng Y; Zhou ZP; Pan CX; Su GF
    J Med Chem; 2017 Aug; 60(16):6853-6866. PubMed ID: 28745887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents.
    Eilon GF; Gu J; Slater LM; Hara K; Jacobs JW
    Cancer Chemother Pharmacol; 2000; 45(3):183-91. PubMed ID: 10663635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
    Zhang K; Hong R; Kaping L; Xu F; Xia W; Qin G; Zheng Q; Lu Q; Zhai Q; Shi Y; Yuan Z; Deng W; Chen M; Wang S
    Cancer Lett; 2019 Apr; 447():130-140. PubMed ID: 30677445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo Study.
    Kuo KL; Liu SH; Lin WC; Hsu FS; Chow PM; Chang YW; Yang SP; Shi CS; Hsu CH; Liao SM; Chang HC; Huang KH
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31262032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells.
    Min A; Kim JE; Kim YJ; Lim JM; Kim S; Kim JW; Lee KH; Kim TY; Oh DY; Bang YJ; Im SA
    Cancer Lett; 2018 Aug; 430():123-132. PubMed ID: 29729292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
    Pancholi S; Ribas R; Simigdala N; Schuster E; Nikitorowicz-Buniak J; Ressa A; Gao Q; Leal MF; Bhamra A; Thornhill A; Morisset L; Montaudon E; Sourd L; Fitzpatrick M; Altelaar M; Johnston SR; Marangoni E; Dowsett M; Martin LA
    Oncogene; 2020 Jun; 39(25):4781-4797. PubMed ID: 32307447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
    El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
    Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
    Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY
    Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.